Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022006545 - COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION

Publication Number WO/2022/006545
Publication Date 06.01.2022
International Application No. PCT/US2021/040356
International Filing Date 02.07.2021
IPC
A61K 47/68 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Applicants
  • INOZYME PHARMA, INC. [US]/[US]
  • WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER [DE]/[DE]
Inventors
  • BANKS, Damon
  • NESTER, Catherine, A.
  • SKOLNIK, Edward
  • WALZ, Markus
  • RUTSCH, Frank
  • NITSCHKE, Yvonne
Agents
  • WILLIAMS, Kathleen, M.
  • DECLOUX, Amy, M.
  • FILANDRIANOS, Emmanuel, D.
  • KLAYMAN, Jeffrey, T.
  • LAXMIKANTHAN, Gurunathan
Priority Data
63/047,79302.07.2020US
63/047,84802.07.2020US
63/047,86502.07.2020US
63/047,87702.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION
(FR) COMPOSITIONS ET MÉTHODES POUR TRAITER UNE VASCULOPATHIE D'ALLOGREFFE, UNE MALADIE DE MOYAMOYA, UN SYNDROME DE MOYAMOYA ET UNE PROLIFÉRATION INTIMALE
Abstract
(EN) The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase- 1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
(FR) La présente divulgation concerne des compositions et des méthodes pour traiter une vasculopathie d'allogreffe, pour traiter des maladies de Moyamoya (MMD) et le syndrome de Moyamoya (MMS), pour traiter l'inhibition ou la prévention de la prolifération intimale indésirable chez un patient par l'administration d'un agent d'ectonucléotide pyrophosphatase / phosphodiestérase-1 (ENPP1) ou d'une ectonucleotide pyrophosphatase / phosphodiestérase-3 (ENPP3).
Latest bibliographic data on file with the International Bureau